Summit C-Suite Risks Success, Akeso Wins Either Way
2025-11-20 19:27:07 ET
Introduction
Akeso ( AKESF ) is a Chinese biotech firm focused on licensing their internal antibody designs to other biotechs. The company is an interesting case for risk tolerant investors seeking long-term opportunities. Akeso has a significant advantage over their partnered firms, such as Summit Therapeutics ( SMMT ), because of the sheer diversity of their pipeline. However, geopolitical risks are no joke, even when the financial opportunity is immense. The shares trade on the OTC markets or internationally in Hong Kong, so the investment is riskier than even a normal biotech investment. Many other headwinds exist, such as expansions to the scope of tariffs or US-led retaliation to biopharma products coming from China, or even potential newly devised provisions in the Biosecure Act that may prohibit US companies from licensing Chinese companies’ IP....
Read the full article on Seeking Alpha
For further details see:
Summit C-Suite Risks Success, Akeso Wins Either Way
NASDAQ: AKESF
AKESF Trading
0.0% G/L:
$17.80 Last:
2,000 Volume:
$17.80 Open:
